Abstract: FR-PO352
Leucine-Rich a-2-Glycoprotein 1 Predicts Cardiovascular Diseases in ESRD Patients
Session Information
- Hypertension and CVD: Clinical, Outcomes, Trials
October 26, 2018 | Location: Exhibit Hall, San Diego Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Hypertension and CVD
- 1402 Hypertension and CVD: Clinical, Outcomes, and Trials
Author
- Yang, Feng-Jung, National Taiwan University Hospital Yulin Branch, Douliu, Taiwan
Background
Plasma Leucine-Rich a-2-Glycoprotein 1 leucine rich α-2 glycoprotein (LRG-1) as a novel serum biomarker for various inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Patients with end-stage renal disease (ESRD) are associated with several health-related adverse outcomes including inflammation, atherosclerosis and premature mortality in individuals. Whether level of Plasma Leucine-Rich a-2-Glycoprotein 1may associate with the clinical status of hemodialysis patients is unknown.
Methods
The immunity in ESRD study (iESRD) recruited 169 hemodialysis patients from southern Taiwan. By history taking and detailed chart reviews, baseline co-morbidities were recorded. Peripheral blood was sampled before hemodialysis session and processed immediately. Plasma levels of LRG1 and high-sensitivity C reactive protein were determined by ELISA. Peripheral blood monocyte and T cell differentiation subsets were determined by multicolor flow cytometry.
Results
Among these patients, 100% were LRG-1-seropositive. In the univariate analysis, log level of LRGwas independently associated with the existence of cardiovascular diseases including stroke and peripheral arterial occlusive disease (OR=111.9 95% CI=2.3-5283.3, p=0.016). In a multivariate-adjusted logistic regression model, log level of LRG was independently associated with the existence of cardiovascular diseases including stroke and peripheral arterial occlusive disease (OR=150.9 95% CI=2.3-9684.8, p=0.018) afteradjusting for gender, hemoglobin, DM, hypertension and hs-CRP. Level of LRG-1 positively correlated with both IL-6, CRP and WBC, indicating the accumulation of these cytokines participate in the progression of atherosclerosis.
Conclusion
LRG-1positively correlates with the existence of cardiovascular diseases in ESRD patients. Role of LRG-1 and the associated inflammation response should be further investigated in the pathogenesis of atherosclerosis in this patient population.